OBJECTIVE: Vinflunine (VFL) is a novel microtubule inhibitor indicated in the treatment of
advanced or metastatic urothelial transitional cell cancer after failure of a prior platinum …

Aims Vinflunine (VFL) ditartrate, a novel tubulin‐targeted inhibitor, is registered for the
treatment of patients with advanced or metastatic urothelial transitional cell carcinoma. This …

15543 Background: Vinflunine (VFL) is a new microtubule inhibitor of the vinca alkaloid
class with clinical activity in TCCU (S. Culine, BJC 2006). This trial was conducted to define …

Vinflunine is a novel bifluorinated vinca alkaloid that appears to differ from other class
members in terms of its tubulin-binding properties and inhibitory effects on microtubule …

Purpose Vinflunine ditartrate is a microtubule inhibitor belonging to the vinca alkaloid family.
This phase I study was carried out to evaluate the maximal tolerated dose, the safety profile …

Background Vinflunine is a new microtubule inhibitor of the vinca-alkaloid family. It is
marketed in transitional cell carcinoma of urothelial tract as a 20 min infusion given every 3 …

Background Vinflunine is recommended in the European guideline for the treatment of
advanced or metastatic urothelial cell carcinoma (UCC) after failure of platinum-based …

Vinflunine is a novel tubulin-targeted agent that is currently indicated as a monotherapy in
bladder cancer patients. The recommended dose of 320 mg/m 2 is given as an intravenous …

Vinflunine is a novel microtubule inhibitor of the vinca alkaloid class currently in
development for the treatment of advanced transitional cell carcinoma of the urothelium …

Relapsed urothelial cancer represents an unmet medical need. Vinflunine is a third-
generation antimicrotubuline inhibitor and is currently the only approved drug for second …